Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 1840

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 7
Chunk 1840
---
 Chief Operating Officer

Michael
Gaul has been our Chief Operating Officer since July 1, 2022. Mr. Gaul joined the Company in May 2020 as Senior VP, Operations, a title
he held until June 2022. Mr. Gaul has led teams in operations, sales and marketing, supply chain, distribution, quality, regulatory, human
resources, and finance. He has had P&L experience with multi-plant responsibility in both the U.S. and Asia, including roles with
Sparton Corporation (Group VP, Manufacturing & Design Services Business Unit; Group VP, Medical Business Unit), a defense contractor
for maritime defense, from September 2011 to February 2020, SynCardia Systems (COO; VP Operations), a manufacturer and provider of the
commercially approved Total Artificial Heart, from June 2005 to February 2011, Ventana Medical Systems (now known as Roche Tissue Diagnostics)
(VP & General Manager, Operations), a medical device company, from September 2003 to April 2005, and Robotic Vision Systems, Inc.
(General Manager, Vanguard Division; VP Operations, Systemation Division), a maker of machine vision systems, from September 1997 to June
2003. He also currently serves on the Board of Directors of the Ohio Life Sciences Association to support and promote Ohio’s bioscience
industry. Mr. Gaul has a BS, Business Administration from Delaware Valley University, and an MBA from Florida Institute of Technology.

Erick J. Lucera, Director

Erick J. Lucera joined our Board
of Directors in August 2017 and serves on our audit committee, compensation committee and nominating committee. DYNE THERAPEUTICS He previously
served as Executive Vice President and Chief Financial Officer of Editas Medicine, Inc., a leading gene editing company focused on developing
CRISPR medicines for people with serious diseases, from May 2023 to March 2025. Mr. Lucera previously served as Chief Financial Officer
of AVEO Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on targeted medicines for oncology and other unmet
medical needs, from January 2020 until March 2023, following its acquisition by LG Chem, Ltd. Since April 2023, Mr. Lucera has served
on the board of directors of SAB Biotherapeutics, Inc., a public clinical-stage biopharmaceutical company. Mr. Lucera was